They proved that serial ctDNA sampling performed better in HCC surveillance than did protein biomarkers such as AFP, AFP-L3 (an isoform of AFP), and des-gamma-carboxy prothrombin, identifying microscopic residual tumors and revealing recurrence before it was revealed by imaging. This evidence concerns the gene AFP and hepatocellular carcinoma.